GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » Debt-to-Revenue

Cryosite (ASX:CTE) Debt-to-Revenue : 0.18 (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Cryosite Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cryosite's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.19 Mil. Cryosite's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$2.17 Mil. Cryosite's annualized Revenue for the quarter that ended in Dec. 2024 was A$13.28 Mil. Cryosite's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.18.


Cryosite Debt-to-Revenue Historical Data

The historical data trend for Cryosite's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryosite Debt-to-Revenue Chart

Cryosite Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.11 0.07 0.22 0.19

Cryosite Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.21 0.20 0.20 0.18

Competitive Comparison of Cryosite's Debt-to-Revenue

For the Diagnostics & Research subindustry, Cryosite's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cryosite's Debt-to-Revenue falls into.


;
;

Cryosite Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cryosite's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.179 + 2.266) / 12.612
=0.19

Cryosite's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.189 + 2.168) / 13.28
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Cryosite Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cryosite's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryosite Business Description

Traded in Other Exchanges
N/A
Address
13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services.

Cryosite Headlines

No Headlines